MRK enters the week with its most defensive options positioning of the past year, even as the Street continues to raise targets — a split that puts the market and analysts squarely at odds.
The options signal is the sharpest data point this week. The put/call ratio jumped to 0.91 on Tuesday, nearly three standard deviations above its 20-day average of 0.74 — the highest reading of the past 52 weeks, bar one session at 0.98. That kind of z-score (2.84) doesn't appear in quiet markets. It reflects genuine demand for downside protection, arriving on the same day the stock slipped a further 0.7% to $143.79. The PCR had been running in a narrow band around 0.70 for most of August. The spike to 0.91 is an abrupt break from that pattern.
Short interest tells a consistent but less extreme story. Shorts have added roughly 26% to their position over the past week, lifting SI to about 1.4% of the free float. That remains a low absolute level for a mega-cap pharma. But the direction matters: SI is up 46% from a month ago, a sustained rebuilding that began in mid-August when the stock was trading in the low $130s. Borrow conditions offer no friction to further shorting — availability is essentially uncapped, cost to borrow sits below 0.4%, and both metrics have been flat for weeks. The shorts are building into a wide-open lending market, which rules out any squeeze dynamic in the near term.
The Street is moving in the opposite direction. Analysts have been raising targets almost uniformly since the August earnings print: Goldman Sachs, UBS, Wells Fargo, Guggenheim, and Leerink have all lifted numbers in the past three weeks, with targets now clustered between $160 and $180. The consensus mean of $152.96 implies roughly 6% upside from current levels. The bull case rests on Keytruda's continued expansion into new indications, a maturing cancer vaccine franchise, and an EPS surprise rank in the 91st percentile — Merck consistently beats. The bear case is well-rehearsed: Keytruda patent exposure in the early 2030s, drug pricing reform risk, and a stock that has now absorbed multiple target upgrades without responding. That last point is the crux. HSBC raised to $172, Leerink to $161, Guggenheim to $170 — all in the past five trading days — and the stock fell through each print. The analyst rec-divergence score ranks in the 92nd percentile, meaning the gap between analyst optimism and market behaviour is near its widest.
Peers add context. JNJ lost less than 1% on the week. LLY gained 1.1%. AZN and GSK rose 2% and 3.2% respectively. MRK's 3.1% weekly decline stands out as the weakest among its closest correlates — suggesting the underperformance is stock-specific, not sector-wide rotation.
Earnings arrive on October 29. The last two prints produced muted moves: the August report generated just a 0.4% next-day gain and a 2.1% five-day follow-through. The May print cost the stock 1.8% on day one and 5.5% over five days. That asymmetry is worth noting — the market rewarded a beat modestly and punished a miss more heavily. With options positioning now at its most defensive of the year and shorts continuing to rebuild, the setup heading into late October is the right thing to watch.
See the live data behind this article on ORTEX.
Open MRK on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
